Description of Business, Organization and Liquidity (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	May 09, 2023 USD ($) $ / shares shares	Apr. 25, 2023	Jan. 04, 2023 USD ($) shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2020 $ / shares
Subsidiary, Sale of Stock [Line Items]
Reverse stock split, conversion ratio		0.5071
Sale of stock, price (in dollars per share) | $ / shares							$ 0.00002
Underwriting discounts, commissions and offering costs				$ 47,354
Temporary equity, convertible, conversion ratio	100.00%			100.00%
Net losses				$ 381,641	$ 64,772	$ 41,839
Research and development				355,886	55,632	38,230
Payments to acquire in-process research and development				10,000	0	25,000
Accumulated deficit				488,719	107,078
Cash used in operating activities				169,705	$ 61,520	$ 4,979
Cash, cash equivalents and short-term marketable securities				721,300
Pierre Fabre
Subsidiary, Sale of Stock [Line Items]
Payments to acquire in-process research and development			$ 10,000	10,000
ValenzaBio Asset Acquisition
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with ValenzaBio acquisition (in shares) | shares			2,013,673
Research and development			$ 123,100	$ 123,100
ValenzaBio Asset Acquisition | Common Class A
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with ValenzaBio acquisition (in shares) | shares			18,885,731
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction (in shares) | shares	34,500,000
Sale of stock, price (in dollars per share) | $ / shares	$ 18.00
Gross proceeds received on transaction	$ 621,000
Net proceeds received on transaction	573,600
Underwriting discounts, commissions and offering costs	$ 47,400
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction (in shares) | shares	4,500,000